Streamlining vaccine development & production with modality-specific purification tools for mRNA & beyond

The COVID-19 pandemic has emphasized the need for readily available commercial-scale vaccine production tools to support global immunization efforts. With an increasing number of novel nucleic acid and viral vector platforms joining vaccine development pipelines, a wider range of purification methods is needed. This Innovator Insight presents case studies of implementing purification tools for rapid candidate screening and intensified downstream processing of various vaccine modalities, including viral vector, virus-like particle, subunit, and mRNA vaccines.

Please enter your email to access content Read now